Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Free Cash Flow: 2009-2025

Historic Free Cash Flow for Corcept Therapeutics (CORT) over the last 12 years, with Sep 2025 value amounting to $54.5 million.

  • Corcept Therapeutics' Free Cash Flow fell 23.97% to $54.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $163.1 million, marking a year-over-year increase of 14.80%. This contributed to the annual value of $195.9 million for FY2024, which is 54.37% up from last year.
  • Corcept Therapeutics' Free Cash Flow amounted to $54.5 million in Q3 2025, which was up 24.15% from $43.9 million recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Free Cash Flow registered a high of $71.7 million during Q3 2024, and its lowest value of $5.0 million during Q1 2025.
  • For the 3-year period, Corcept Therapeutics' Free Cash Flow averaged around $38.7 million, with its median value being $42.2 million (2023).
  • Per our database at Business Quant, Corcept Therapeutics' Free Cash Flow crashed by 82.35% in 2023 and then surged by 914.25% in 2024.
  • Over the past 5 years, Corcept Therapeutics' Free Cash Flow (Quarterly) stood at $49.4 million in 2021, then slumped by 32.42% to $33.4 million in 2022, then slumped by 82.35% to $5.9 million in 2023, then spiked by 914.25% to $59.7 million in 2024, then fell by 23.97% to $54.5 million in 2025.
  • Its Free Cash Flow was $54.5 million in Q3 2025, compared to $43.9 million in Q2 2025 and $5.0 million in Q1 2025.